Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Lydia Scarfò, MD
Advertisement
Articles by Lydia Scarfò, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves PGDx Elio Tissue Complete CDx for Advanced Melanoma
2
Divesiran Shows Clinical Responses in Phase 2 Polycythemia Vera Trial
3
177Lu-Edoterotide Handed CRL by FDA For GEP-NETs Treatment
4
How Will ARNT Expression and Novel Combinations Shape RCC Treatment?
5